Clinical trial NCT00591266: Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Keywords: Blood pressure
blood pressure monitoring ambulatory
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2008-01-11
Enrollment: 566
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.

Detailed description: Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system, a system of hormone-mediated feedback interactions that results in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system with a myriad of effects on the cardiovascular system and on electrolyte homeostasis.

Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat patients with essential hypertension. Azilsartan medoxomil is a prodrug that is hydrolyzed to the active moiety, azilsartan, which is a selective antagonist of the angiotensin II type 1 receptor subtype.

Amlodipine is a slow-channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

This study is being conducted to determine whether administration of azilsartan medoxomil in combination with amlodipine in participants with uncontrolled hypertension is more efficacious in reducing systolic blood pressure than amlodipine alone. Participation in this study is anticipated to be approximately 10 weeks.

Eligibility criteria: Inclusion Criteria:

1. Has essential hypertension and 24-hour mean systolic blood pressure greater than or equal to 140 mm Hg and less than or equal to 180 mm Hg.
2. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study
3. Has clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.
4. Is willing to discontinue current antihypertensive medications.

Exclusion Criteria:

1. Has sitting trough clinic diastolic blood pressure greater than 119 mm Hg.
2. Has a baseline 24 hour ambulatory blood pressure monitoring reading of insufficient quality.
3. The subject is hypersensitive to angiotensin II receptor blockers or calcium channel blockers.
4. Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
5. Has clinically significant cardiac conduction defects.
6. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
7. Has secondary hypertension of any etiology
8. Is non-compliant with study medication during placebo run-in period.
9. Has severe renal dysfunction or disease.
10. Has known or suspected unilateral or bilateral renal artery stenosis.
11. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
12. Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
13. Has type 1 or poorly controlled type 2 diabetes mellitus.
14. Has hyperkalemia as defined by the central laboratory normal reference range,
15. Has an alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease or jaundice.
16. Has an upper arm circumference less than 24 cm or greater than 42 cm.
17. Works night (3rd) shift.
18. Currently participating in another investigational study or has participated in an investigational study within 30 days prior to randomization.
19. Has any other serious disease or condition that would compromise subject safety or make it difficult to successfully manage and follow the subject according to the protocol.
20. Has been randomized in a previous TAK-491 study.
21. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.

Primary outcomes:
measure: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
Secondary outcomes:
measure: Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
timeFrame: Baseline and Week 6.
measure: Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
timeFrame: Baseline and Week 6.
measure: Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
timeFrame: Baseline and Week 6.
measure: Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
timeFrame: Baseline and Week 6.
measure: Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
timeFrame: Baseline and Week 6.
Other outcomes:
Locations:
city: Mesa
country: United States
state: Arizona
city: Phoenix
country: United States
state: Arizona
city: Anaheim
country: United States
state: California
city: Beverly Hills
country: United States
state: California
city: Burbank
country: United States
state: California
city: Burlingame
country: United States
state: California
city: La Jolla
country: United States
state: California
city: Orange
country: United States
state: California
city: Roseville
country: United States
state: California
city: Tustin
country: United States
state: California
city: Wheat Ridge
country: United States
state: Colorado
city: Newark
country: United States
state: Delaware
city: Washington
country: United States
state: District of Columbia
city: Hialeah
country: United States
state: Florida
city: Longwood
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Honolulu
country: United States
state: Hawaii
city: Boise
country: United States
state: Idaho
city: Chicago
country: United States
state: Illinois
city: Gurnee
country: United States
state: Illinois
city: Peoria
country: United States
state: Illinois
city: Elkhart
country: United States
state: Indiana
city: Crestview Hills
country: United States
state: Kentucky
city: Lexington
country: United States
state: Kentucky
city: Riverdale
country: United States
state: Maryland
city: Brockton
country: United States
state: Massachusetts
city: Haverhill
country: United States
state: Massachusetts
city: North Dartmouth
country: United States
state: Massachusetts
city: Kansas City
country: United States
state: Missouri
city: Omaha
country: United States
state: Nebraska
city: Raleigh
country: United States
state: North Carolina
city: Akron
country: United States
state: Ohio
city: Canton
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Mogadore
country: United States
state: Ohio
city: Norman
country: United States
state: Oklahoma
city: Tulsa
country: United States
state: Oklahoma
city: Warminster
country: United States
state: Pennsylvania
city: Cumberland
country: United States
state: Rhode Island
city: Arlington
country: United States
state: Texas
city: Austin
country: United States
state: Texas
city: Carrollton
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Irvine
country: United States
state: Texas
city: Lake Jackson
country: United States
state: Texas
city: North Richland Hills
country: United States
state: Texas
city: Manassas
country: United States
state: Virginia
city: Renton
country: United States
state: Washington
city: Menomonee Falls
country: United States
state: Wisconsin
Study officials:
affiliation: Takeda
name: Executive Medical Director Clinical Science
role: STUDY_DIRECTOR
References: